Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study
José F. Camargo, Rick Y. Lin, Yoichiro Natori, Anthony D. Anderson, Maritza C. Alencar, Trent Wang, Michele I. Morris, Krishna V. Komanduri
Abstract
Key Points Shingrix is poorly immunogenic following allogeneic hematopoietic cell transplantation independent of age, CD4, and B-cell recovery. In hematopoietic cell transplantation recipients with antibody response to the vaccine, varicella zoster virus reactivation risk is not null.
Topics & Concepts
ImmunogenicityHematopoietic cellHematopoietic stem cell transplantationImmunologyVirologyMedicineTransplantationHaematopoiesisVirusAntibodyVaricella zoster virusBiologyInternal medicineStem cellGeneticsHerpesvirus Infections and TreatmentsPoxvirus research and outbreaksAnimal Virus Infections Studies